TNF and Cowden disease: Between Ustekinumab and Risankizumab, in the SEQUENCE trial (Nct, 2020), a phase 3 head-to-head study compared these two interleukin antagonists for the treatment of patients with moderate-to-severe CD who have failed at least one TNF antagonists.